{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreifg5xwoixkc54qddxg4h25aes3pvszf5dlqzlgpjaa5hj7pzfjn4y",
    "uri": "at://did:plc:svcthvzunxmjidtlw23zva6n/app.bsky.feed.post/3mkgwnxygvhe2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreieytwyoxr57yfjqbqqjgleseh5a7xezyvfqmuyar6zwzq4nsnm5z4"
    },
    "mimeType": "image/jpeg",
    "size": 10925
  },
  "path": "/2026/04/27/ascletis-completes-enrollment-in-u-s-phase-ii-study-of-asc30-an-oral-small-molecule-glp-1r-agonist-for-the-treatment-of-diabetes/",
  "publishedAt": "2026-04-27T00:10:00.000Z",
  "site": "https://laotiantimes.com",
  "tags": [
    "Cision PR Newswire"
  ],
  "textContent": "– 13-week U.S. Phase II study is evaluating the efficacy, safety and tolerability of oral small molecule GLP-1R agonist ASC30, a once-daily tablet, in 100 participants with diabetes. – Topline data from the Phase II study are expected in the third quarter of 2026. HONG KONG, April 27, 2026 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: […]",
  "title": "Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes"
}